| Literature DB >> 28740812 |
Hagar Tadmor1,2, Maya Levin2, Tzameret Dadon1, Meital E Meiman1, Alaa Ajameeh1, Hosam Mazzawi1, Amihai Rigbi3,4, Ilana Kremer1,5, Idit Golani6, Alon Shamir1,5.
Abstract
The deficit in ability to attribute mental states such as thoughts, beliefs, and intentions of another person is a key component in the functional impairment of social cognition in schizophrenia. In the current study, we compared the ability of persons with first episode schizophrenia (FE-SZ) and individuals with schizophrenia displaying symptomatic remission (SZ-CR) to decode the mental state of others with healthy individuals and schizoaffective patients. In addition, we analyzed the effect of dopamine-related genes polymorphism on the ability to decode the mental state of another, and searched for different genetic signatures. Our results show that overall, individuals with schizophrenia performed worse in the "Reading the Mind in the Eyes" (eyes) test, a simple well-defined task to infer the mental state of others than healthy individuals. Within the schizophrenia group, schizoaffective scored significantly higher than FE-SZ, SZ-CR, and healthy individuals. No difference was observed in performance between FE-SZ and SZ-CR subjects. Interestingly, FE-SZ and SZ-CR, but not schizoaffective individuals, performed worse in decoding negative and neutral emotional valance than the healthy control group. At the genetic level, we observed a significant effect of the DAT genotype, but not D4R genotype, on the eyes test performance. Our data suggest that understanding the mental state of another person is a trait marker of the illness, and might serve as an intermediate phenotype in the diagnostic process of schizophrenia disorders, and raise the possibility that DA-related DAT gene might have a role in decoding the mental state of another person.Entities:
Keywords: Dopamine; Dopamine transporter; Mental state decoding; Schizophrenia; Theory of mind
Year: 2016 PMID: 28740812 PMCID: PMC5514298 DOI: 10.1016/j.scog.2016.06.001
Source DB: PubMed Journal: Schizophr Res Cogn ISSN: 2215-0013
Demographic, clinical and genetics data.
| Variable category | Variable | SZ-CR (41) | SZ-AF (9) | FE-SZ (20) | Controls (200) | |
|---|---|---|---|---|---|---|
| Demographic | ||||||
| Age, yrs.: mean (SD) | 35.6 (10.0) | 41.6 (8.3) | 26.4 (4.9) | 26.5 (7.5) | ||
| Education, yrs.: mean (SD) | 11.8 (2.2) | 11.3 (2.2) | 12.0 (1.6) | 13.8 (2.6) | ||
| Gender: n (%) | ||||||
| Men | 34 (83%) | 7 (78%) | 16 (80%) | 106 (54%) | ||
| Women | 7 (17%) | 2 (22%) | 4 (20%) | 92 (46%) | ||
| Nationality: n (%) | 0.1 | |||||
| Jewish | 33 (81%) | 9 (100%) | 12 (60%) | 146 (73%) | ||
| Arab | 8 (19%) | 0 (0%) | 8 (40%) | 53 (27%) | ||
| Ethnicity: n (%) | ||||||
| Ashkenazi | 17 (55%) | 5 (56%) | 11 (92%) | 67 (46%) | ||
| Non-Ashkenazi | 14 (45%) | 4 (44%) | 1 (8%) | 79 (54%) | ||
| Onset, yrs.: mean (SD) | 25.1 (7.3) | 26.1 (8.3) | 25.5 (4.7) | NA | 0.91 | |
| Years of illness: mean (SD) | 11.0 (7.2) | 15.4 (7.9) | 1.1 (0.6) | NA | ||
| No. of hospitalizations: mean (SD) | 6.2 (5.0) | 8.5 (6.9) | 1.0 (0.0) | NA | ||
| PANSS scales score: mean (SD) | ||||||
| Positive items | 21.9 (6.4) | 17.3 (4.0) | 41.7 (4.6) | NA | ||
| Negative items | 26.2 (5.8) | 17.8 (5.2) | 22.8 (5.8) | NA | ||
| General items | 48.3 (7.4) | 45.9 (5.4) | 58.5 (6.2) | NA | ||
| Total | 96.1 (14.7) | 77.2 (12.6) | 122.9 (10.4) | NA | ||
| Smoking status: n (%) | ||||||
| Yes | 24 (60%) | 7 (78%) | 14 (70%) | 46 (23%) | ||
| No | 16 (40%) | 2 (22%) | 6 (30%) | 153 (77%) | ||
| DAT polymorphism: n (%) | 0.71 | |||||
| Homozygote 9/9 | 6 (17%) | 0 (0%) | 4 (20%) | 22 (16%) | ||
| Homozygote 10/10 | 17 (49%) | 5 (63%) | 7 (35%) | 55 (39%) | ||
| Heterozygote 9/10 | 12 (34%) | 3 (37%) | 9 (45%) | 64 (45%) | ||
| D4R polymorphism: n (%) | 0.18 | |||||
| Short allele | 21 (62%) | 2 (25%) | 14 (70%) | 78 (61%) | ||
| Long allele | 13 (38%) | 6 (75%) | 6 (30%) | 50 (39%) | ||
Abbreviations: DAT, dopamine active transporter; D4R, dopamine D4 receptor; PANSS, positive and negative syndrome scale; SZ, chronic schizophrenia; SZ-AF, schizoaffective; FE-SZ, first episode schizophrenia; CT, control group SD, standard deviation.
Post hoc comparisons revealed that the SZ and SZ-AF groups were significantly older than the other groups (p < 0.001 for all comparisons).
Post hoc comparisons revealed that the control group had significantly more years of education than the schizophrenic groups (p < 0.001, p = 0.02, p = 0.02, respectively).
This variable is relevant only for Jewish participants.
Post hoc comparisons revealed that the FE-SZ group length of illness was significantly shorter than the other schizophrenic groups (p < 0.001 for all comparisons).
Post hoc comparisons revealed that the FE-SZ group number of hospitalizations was significantly smaller than the other schizophrenic groups (p < 0.001 for SCZ, p = 0.001 for schizoaffective comparisons).
Post hoc comparisons revealed that the FE-SZ group PANSS-positive score was significantly higher than the other schizophrenic groups (p < 0.001 for all comparisons).
Post hoc comparisons revealed that SZ-AF PANSS-negative score was significantly lower than the other schizophrenic groups (p = 0.001).
Post hoc comparisons revealed that FE-SZ group PANSS-general score was significantly higher than the other schizophrenic groups (p < 0.001 for all comparisons).
Post hoc comparisons revealed that the first episode group PANSS-total score was significantly higher than the other schizophrenic groups (p < 0.001 for all comparisons); the total score of SZ-CR group was significantly higher that the SZ-AF group (p = 0.001).
Fig. 1Individuals with schizophrenia are impaired in decoding the emotional state of others. Healthy volunteers (A) and schizophrenic patients (B) total eyes test score distribution. C) Estimated mean differences in total eyes test score ± SEM between overall schizophrenia groups and control group. **p < 0.001.
Fig. 2Decoding negative and neural valences is altered in the schizophrenia patients group. Estimated mean differences of presented correct choices ± SEM (A) negative emotional valence, (B) neutral emotional valence, and (C) positive emotional valence. **p < 0.001.
Fig. 3Schizoaffective individuals performed better in the eyes test. (A) Estimated mean differences in total eyes test score ± SEM between individuals with schizophrenia first episode, schizoaffective, and healthy subjects. Estimated mean differences of presented of correct choices ± SEM (B) negative emotional valence, (C) neutral emotional valence, and (D) positive emotional valence. *p < 0.5, **p < 0.001, ***p < 0.0001.